In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

The Mayo Clinic estimates that menopause symptoms lead to $1.8 billion in lost work time per year in the U.S. About 5 percent of employers offer menopause benefits or accommodations such as the ...

Q4 2024 Earnings Call Transcript March 10, 2025 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, ...

(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

CVRM product development global head and senior vice-president Manu Chakravarthy will be the centre's site head.

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.

F. Hoffmann-La Roche, one of the world’s largest biotechnology companies, announced on Thursday that it will establish an ...